Additionally, mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2 and mutated TP53 are also classified as adverse risk [24]; and if adverse-risk cytogenetic abnormalities are present in NPM1-mutated AML, they are also classified as adverse risk [24]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.